For informational purposes only — not investment advice

← Back to signals

BSX

LONGINSIDER BUY

BOSTON SCIENTIFIC CORP

Funds
3
Score
4.50
vs SPY
-39.3%
Stock return (since Q-end)
-23.0%
SPY return (since Q-end)
+16.3%
Current price
$48.31

News Summary

Negative

Boston Scientific reported Q1 2026 earnings that beat consensus but triggered significant guidance cuts, lowering FY2026 organic growth from 10-11% to 6.5-8% and reducing revenue guidance by ~$700M due to unexpected weakness in EP, WATCHMAN, and Urology segments. A securities class action lawsuit alleges material misstatements about EP business conditions, and the stock has declined 31% YTD with analyst price targets cut by 28% on average, reflecting sustained competitive and operational headwinds.

Red flags

  • FY2026 organic growth guidance slashed from 10-11% to 6.5-8% and full-year revenue cut by ~$700M (~3.2%)
  • WATCHMAN franchise flagged as potentially stagnating with flat sequential revenue expected in Q2-Q3
  • EP (electrophysiology) business showing competitive share losses and market softness despite prior claims of sustained high growth
  • Securities class action lawsuit alleging material misstatements about EP business and FARAPULSE platform performance between July 2025-Feb 2026
  • Stock down 31% YTD and down 17.6% on single day (Feb 4, 2026) following EP growth revelation
  • Five named executives listed in fraud suit including CEO Michael Mahoney and CFO Jonathan Monson
  • Multiple analyst downgrades and average price target reduction of 28% in past 3 months; Wells Fargo and Daiwa moved to Equal Weight/Neutral
  • Margin pressure cited from tariffs and reimbursement headwinds; hospital capacity constraints affecting key franchises

Funds Buying (3)

FundManagerShares Held∆ SharesPosition ValueQoQStatus
Maverick CapitalLee Ainslie4.2M+4.2M$263.2BNEW
Point72Steve Cohen3.7M+3.7M$231.4BNEW
Lone Pine CapitalSteve Mandel105K+105K$6.6BNEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.

Insider Activity

NameTitleTypeSharesPriceValueFiled
Pegus CherylBUY2K$56.49$0.10M2026-05-20
LUDWIG EDWARD JBUY4K$56.68$0.20M2026-05-20
Habiger David CBUY2K$55.92$0.13M2026-05-20
Habiger David CBUY2K$56.95$0.13M2026-05-19